Mabpharm Limited (02181) announced its monthly return for February 2026, reporting an authorized share capital of 50.00 billion ordinary shares at a par value of USD 0.0001, totaling USD 5.00 million.

The total issued shares remain at 4.12 billion with zero treasury shares. The public float requirement stands at 25%, with compliance confirmed. Meanwhile, 72.67 million share options remain outstanding under the share option scheme, with no changes during the month. There are no warrants, convertibles, or other share arrangements. The announcement was submitted on 03 March 2026.